

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Pyridostigmine compared to Standard treatment be used for COVID-19 patients?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pyridostigmine	Standard treatment	Relative (95% CI)	Absolute (95% CI)	
<b>All-cause mortality</b>											
1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	7/94 (7.4%)	19/94 (20.2%)	<b>RR 0.37</b> (0.16 to 0.83)	<b>127 fewer per 1.000</b> (from 170 fewer to 34 fewer)	⊕⊕⊕○ MODERATE
<b>Number of patients with Progression / exacerbation of disease</b>											
1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	6/94 (6.4%)	7/94 (7.4%)	<b>RR 0.86</b> (0.30 to 2.46)	<b>10 fewer per 1.000</b> (from 52 fewer to 109 more)	⊕⊕⊕○ MODERATE
<b>Number of patients with any adverse event</b>											
1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	45/94 (47.9%)	38/94 (40.4%)	<b>RR 1.18</b> (0.86 to 1.64)	<b>73 more per 1.000</b> (from 57 fewer to 259 more)	⊕⊕⊕○ MODERATE
<b>Number of patients with serious adverse events</b>											
1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	very serious <sup>b</sup>	none	3/94 (3.2%)	3/94 (3.2%)	<b>RR 1.00</b> (0.21 to 4.83)	<b>0 fewer per 1.000</b> (from 25 fewer to 122 more)	⊕⊕○○ LOW
<b>Number of patients discharged</b>											
1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	serious <sup>a</sup>	none	85/94 (90.4%)	71/94 (75.5%)	<b>RR 1.20</b> (1.05 to 1.37)	<b>151 more per 1.000</b> (from 38 more to 279 more)	⊕⊕⊕○ MODERATE

**Explanations**

- a. Downgraded of one level for small sample size (<200)
- b. Downgraded of two levels for small sample size and wide Confidence Interval

## References

1. Fragoso-Saavedra S, Núñez I, Audelo-Cruz MB, Arias-Martínez S, Manzur-Sandoval D, Quintero-Villegas A, et al. Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial. medRxiv 2021.04.28.21255834; doi: <https://doi.org/10.1101/2021.04.28.21255834>